Sight Sciences (SGHT)
(Real Time Quote from BATS)
$6.60 USD
+0.08 (1.23%)
Updated May 31, 2024 10:32 AM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SGHT 6.60 +0.08(1.23%)
Will SGHT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SGHT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGHT
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
SGHT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sight Sciences (SGHT) to Expand in Europe With New Launch
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Other News for SGHT
Predictive Oncology, Augmedix, Cue Health among healthcare movers
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNIĀ® Across Mild, Moderate, and Advanced Glaucoma
Sight Sciences announces publication of analysis from ROMEO study
Sight Sciences publishes SAHARA RCT data demonstrating improved DED symptoms